INSIGHTS ON CLINICAL TRIAL DESIGN

• The Psychedelic Setback: What MDMA Rejection Taught Drug Developers

  Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.

• Improving The eCOA Experience

  Discover how template-driven builds and reuse can slash eCOA timelines by 50% while solving the licensing and translation hurdles that delay First Patient In.

• Navigating The Complexities Of Cross-Border Clinical Trials

  Explore the regulatory, logistical, and patient-centered challenges of cross-border clinical trials, including insights on enhancing collaboration and prioritizing patients in global research.

• Optimizing Clinical Supply Flexibility With Demand-Led Strategies

  Explore demand-led supply strategies for clinical trials. Compare traditional vs. DLS models and learn when pack-to-order, pack-to-stock, or hybrid approaches optimize supply flexibility.

• Ophthalmology Patient Engagement And Retention: Point-Of-Need Execution

  4/6/2026

  Dropout in retinal trials is often a logistical failure. Reducing travel burden and bringing specialized care to the patient can slash attrition rates and secure critical trial timelines.

• Evaluating Adaptive Trials: Do They Align With Your Study's Goals?

  4/10/2025

  In this short video as Robin Bliss, Vice President, Strategic Consulting at Veristat, shares four key questions that she likes to ask when planning an adaptive design clinical trial.

• How Pharmacometrics Informs Dose Selection And Biomarker Decisions

  6/10/2026

  Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

• Keeping Oncology Programs Moving As Complexity Increases

  5/1/2026

  As oncology trials grow more complex, speed depends on clarity. Consistent oversight and shared data help teams make confident decisions faster without losing control.

• De-Risking Early-Stage Biotech: Turning Vision Into Venture Capital

  9/3/2025

  For early-stage biotech companies, transforming a scientific breakthrough into an investable asset requires more than compelling data—it requires a clear product vision.